ArticleNational science review2026
LamNet: an alchemical-path-aware graph neural network to accelerate binding free energy calculations for drug discovery and beyond.
Article in National science review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AI decodes protein-ligand binding.Nature chemical biology · 2026Article
- From undruggable to degradable: A deep learning-enabled framework for precision orthopaedic protein degradation.Journal of orthopaedic translation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate prediction of protein-ligand binding free energies is critical yet computationally demanding in drug discovery. Alchemical free energy methods (AFEMs) offer high accuracy but suffer from significant computational costs and complex modeling setup, such as tuning the λ-schedule of alchemical transformation. While conventional deep learning (DL) models may instantly predict binding affinity, they often require a large training set and exhibit limited generalizability across chemical space. To address these challenges, we introduce LamNet, an alchemical-path-aware graph neural network. LamNet integrates endpoint molecular states and the bridging alchemical path (parametrized by λ) into a physics-informed representation learning framework, explicitly modeling free energy changes along a chosen thermodynamic transformation pathway. Trained on molecular-dynamics-simulated data along alchemical pathways and incorporating data reliability metrics, LamNet accurately predicts relative binding free energies and absolute binding free energies, and optimizes λ-schedules to improve traditional AFEM convergence. Evaluations on diverse datasets (463 ligands, 16 proteins) demonstrate that LamNet achieves superior or comparable performance to state-of-the-art methods, including traditional AFEM, but with up to 1000-fold acceleration. These findings establish LamNet as a generalizable, physics-grounded, and cost-effective tool that not only accelerates computations but also provides a novel framework for integrating rigorous computational physics into modern DL-driven drug discovery workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.